Characterization of Pseudomonas aeruginosa isolated from chronically infected children with cystic fibrosis in India

BMC Microbiology

Volumn 5, Issue , 2005, Pages

  Agarwal, Gunjan ^a   Kapil, Arti ^a   Kabra, Susheel Kumar ^a   Das, Bimal Kumar ^a   Dwivedi, Sada Nand ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARGININE; BETA LACTAMASE; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; METHIONINE; PIPERACILLIN;

ARTICLE; AUXOTROPHY; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHILD; CHILD HOSPITALIZATION; CHRONIC DISEASE; CHRONICITY; CONTROLLED STUDY; CYSTIC FIBROSIS; DEATH; ENZYME SYNTHESIS; FEMALE; FOLLOW UP; GENOTYPE; GRAM NEGATIVE INFECTION; HUMAN; INDIA; INFANT; MAJOR CLINICAL STUDY; MALE; MORPHOTYPE; MULTIDRUG RESISTANCE; PEDIATRICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; SPECIES DIVERSITY;

ADOLESCENT; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INDIA; MALE; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RIBOTYPING;

PSEUDOMONAS AERUGINOSA;

EID: 23944517102     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-5-43     Document Type: Article

References (46)

1. Ahuja AS, Kabra SK: Cystic fibrosis: Indian experience. Ind Pediatr 2002, 39:813-818.
2. Singh M, Prasad R, Kumar L: Cystic fibrosis in north Indian children. Ind J Pediatr 2002, 69:627-629.
3. Kabra SK, Kabra M, Lodha R, Shastri S, Ghosh M, pandey RM, Kapil A, Aggarwal G, Kapoor V: Clinical profile and frequency of delta 508 mutation in Indian children with cystic fibrosis. Ind Pediatr 2003, 40:612-619.
4. Koch C, Hoiby N: Pathogenesis of cystic fibrosis. Lancet 1993, 341:1065-1069.
5. Kulczycki LL, Murphy TM, Bellanti JA: Pseudomonas colonization in cystic fibrosis. JAMA 1978, 240:30-34.
6. Friend PA: Pulmonary infection in cystic fibrosis. J Infect 1986, 13:55-72.
7. Govan JR, Deretic V: Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996, 60:539-74.
8. Mearns MB, Hunt GH, Rushworth R: Bacterial flora of respiratory tract in patient with cystic fibrosis. Arch Dis Child 1971, 47:902-07.
9. Cheng K, Smith R, Govan JRW, Catherine D, Winstanley Denning N: Spread of beta lactam resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996, 348:639-42.
10. Saiman L, Mehar F, Niu W, Neu HC, Shaw KJ, Millar G, Prince A: Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from CF patients, including transplant candidates. Clin Infect Dis 1996, 23:532-537.
11. Oliver A, Canton R, Baquero F, Blazquez J: High frequency of Hypermutable P. aeruginosa in cystic fibrosis lung infection. Science 2000, 288:1251-1253.
12. Agarwal G, Kapil A, Kabra SK, Chandra R, Das B; Dwivedi SN: Phenotypic and Genotypic variants of Pseudomonas aeruginosa isolated from Cystic Fibrosis Children in India. Ind J Med Res 2002, 116:73-81.
13. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP: Random Amplified DNA Typing of Pseudomonas aeruginosa Isolates Recovered from Patients with Cystic Fibrosis. J Clin Microbiol 1996, 34:1129-1135.
14. Barth AL, Pitt TL: The high amino acid content of sputum from cystic fibrosis patients promotes the growth of auxotrophic P. aeruginosa. J Med Microbiol 1996, 45:110-119.
15. Belkum AV, Renders NHM, Smith S, Overbeek SE, Verbrugh HA: Comparison of conventional and molecular methods for the detection of bacterial pathogens in sputum samples from cystic fibrosis patients. FEMS Immuno Med Microbiol 2000, 27:51-57.
16. Cystic Fibrosis Foundation: Patient Registry 1998 annual data repot. Bethesda MD: Cystic fibrosis Foundation; 1999.
17. Power CA, Potter EM, Wessel HU, Lloyd Still JD: Cystic fibrosis in Asian Indians. Arch Pediatr Adolesc Med 1996, 150:554-555.
18. FitzSimmons S: The changing epidemiology of cystic fibrosis. J Pediatr 1993, 122:1-9.
19. Govan JRW, Nelson JW: Microbiology of lung infections in cystic fibrosis. Br Med Bull 1992, 48:912-930.
20. Gilligan PH: Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991, 4:35-51.
21. Fick RB Jr: Pathogenesis of Pseudomonas aeruginosa lung lesion in cystic fibrosis. Chest 1989, 96:158-164.
22. Barth AL, Pitt TL: Microbial pathogens associated with Cystic fibrosis: special focus on P. aeruginosa. Braz J Infect Dis 1998, 2:43-61.
23. Burns JL, Ramsey BW, Smith AL: Clinical manifestations and treatment of pulmonary infections in cystic fibrosis. Adv Pediatr Infect Dis 1993, 8:53-66.
24. Mouton JW, Hollander JGD, Horrevorts AM: Emergence of antibiotic resistance amongst P. aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1993, 31:919-926.
25. Ogle JW, Reller LB, Vasil ML: Development of resistance in P. aeruginosa to imipenam, norfloxacin and ciprofloxacin during therapy: proof provided by typing with a DNA probe. J Infect Dis 1988, 157:743-8.
26. Kfoury JNS, Araj GF: Recent developments in β lactamases and extended spectrum β lactamases. BMJ 2003, 327:1209-13.
27. Pederson SS: Lung infection with alginate producing, mucoid Pseudomonas aeruginosa in cystic fibrosis. APMIS 1992, 28:1-79.
28. Thomassen MJ, Demko CA, Boxerbaum B, Stern RC, Kuchenbrod PJ: Multiple isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis 1979, 140:873-80.
29. Govan JRW, Fyfe JAM: Mucoid Pseudomonas aeruginosa and cystic fibrosis: resitance of the mucoid form to carbenicillin, flucloxacillin, and tobramycin and the isolation of mucoid variants in vitro. J Antimicrob Chemother 1978, 4:233-240.
30. Demko CA, Thomassen : Effect of mucoid property on antibiotic susceptibility of P. aeruginosa. Curr Microbiol 1980, 4:69-73.
31. Tannenbaum CS, Hastie AT, Higgins ML, Kueppers F, Weinbaum G: Inability of purified Pseudomonas aeruginosa exopolysaccharide to bind selected antibiotics. Antimicrob Agents Chemother 1984, 25:673-5.
32. Nicholas WW, Evans MJ, Slack MPE, Walmsley HL: The penetration of antibiotics into aggregrates of mucoid and nonmucoid P. aeruginosa. J gen Microbiol 1989, 135:1291-1303.
33. Taylor RFH, Hodson ME, Pitt TL: Adult cystic fibrosis association of acute pulmonary exacerbation and increasing severity of lung disease with auxotrophic mutants of P. aeruginosa. Thorax 1993, 48:1002-5.
34. Barth AL, Pitt TL: Auxotrophic variants of Pseudomonas aeruginosa are selected from prototrophic wild type strains in respiratory infections in patients with cystic fibrosis. J Clin Microbiol 1995, 33:37-40.
35. The International P. aeruginosa Typing Study Group: A multicenter comparison of methods for typing strains of P. aeruginosa predominantly from patients with cystic fibrosis. J Infect Dis 1994, 169:134-142.
36. Severino P, Darini AL, Magalhaes VD: The discriminatory power of ribo-PCR compared to conventional ribotyping for epidemiological purposes. APMIS 1999, 107:1079-84.
37. Speert DP, Campbell ME: Hospital epidemiology of Pseudomonass aeruginosa from patients with cystic fibrosis. J Hosp Infect 1987, 9:11-21.
38. Speert DP, Lawton D, Damm S: Communicability of Pseudomonas aeruginosa in a cystic fibrosis summer camp. J Pediatr 1982, 101:227-229.
39. Renders NHM, Sijmons MAF, Van Belkum A, Overbeek E, Mouton JW, Verbrugh HA: Exchange of Pseudomonas aeruginosa strains among cystic fibrosis siblings. Res Microbiol 1997, 148:447-454.
40. Silbert S, Barth AL, Sadar HS: Heterogeneity of P. aeruginosa in Brazilian Cystic Fibrosis Patients. J Clin Microbiol 2001, 39:3976-3981.
41. Burns JL, Gibson RL, McNamara S, Yuin D, Emerson J, Rosenfeld M, et al.: Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001, 183:444-52.
42. Boat TF, Wesh MJ, Beaudet A, et al.: Cystic Fibrosis. In The metabolic basis of inherited diseases Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D, Stansbury JB, Wyngaorden JB. New York: Mc GrawHill; 1989:2649-2680.
43. Kabra SK, Alok A, Kapil A, Aggarwal G, Kabra M, Lodha R, et al.: Can Throat Swab after physiotherapy replace sputum for identification of microbial pathogens in children with cystic fibrosis? Ind J Ped 2004, 71:21-23.
44. Govan JRW: Pseudomonas, Stenotrophomonas, Burkholderia. In Practical Medical Microbiology 14th edition. Collee JG, Fraser AG, Marmion BP and Simmons A. New York: Churchill Livingstone; 1996:413-424.
45. National Committee for Clinical Laboratory Standards: MIC testing-supplement tables. Approved standard M100-S10(M7). National Committee for Clinical Laboratory Standards, Wayne, Pa; 2000.
46. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A7. NCCLS Document M2-A7. 7th edition. National Committee for Clinical Laboratory Standards, Wayne, Pa; 2000.